Professional Summary »
Specializing In »
Practice Locations »
Patient Ratings »
Referring Physicians »
Professional Summary
Education & Certifications
- Internship: Cedars Sinai Medical Center Internal Medicine Residency (1998) CA
- Fellowship: Stanford University Bone Marrow Transplant Fellowship (2016) CA
- Board Certification: American Board of Internal Medicine, Medical Oncology (2015)
- Board Certification: American Board of Internal Medicine, Hematology (2015)
- Fellowship: Loma Linda University Hematology and Medical Oncology Fellowship (2015) CA
- Board Certification: American Board of Internal Medicine, Internal Medicine (2000)
- Residency: St Mary's Medical Center Internal Medicine Residency (2000) CA
- Medical Education: Kilpauk Medical College (1995) India
Publications
-
Adoption of pediatric-inspired acute lymphoblastic leukemia regimens by adult oncologists treating adolescents and young adults: A population-based study.
Muffly, L., Lichtensztajn, D., Shiraz, P., Abrahão, R., McNeer, J., Stock, W., … Gomez, S. L. (2016). Adoption of pediatric-inspired acute lymphoblastic leukemia regimens by adult oncologists treating adolescents and young adults: A population-based study. Cancer. -
Pharmacologic maintenance strategies following allogeneic hematopoietic cell transplantation for acute myeloid leukemia.
Lee, C. J., Shiraz, P., & Muffly, L. (2017). Pharmacologic maintenance strategies following allogeneic hematopoietic cell transplantation for acute myeloid leukemia. Leukemia & Lymphoma, 58(3), 516–27. -
Adoption of Pediatric-Inspired Acute Lymphoblastic Leukemia Regimens by Adult Oncologists Treating Adolescents and Young Adults: A Population-Based Study
Muffly, L., Lichtensztajn, D., Shiraz, P., Abrahao, R., McNeer, J., Stock, W., … Gomez, S. L. (2017). Adoption of Pediatric-Inspired Acute Lymphoblastic Leukemia Regimens by Adult Oncologists Treating Adolescents and Young Adults: A Population-Based Study. CANCER, 123(1), 122–30. -
Advance Directive Utilization is Associated with Less Aggressive End-of-Life Care in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation.
Cappell, K., Sundaram, V., Park, A., Shiraz, P., Gupta, R., Jenkins, P., … Muffly, L. (2018). Advance Directive Utilization is Associated with Less Aggressive End-of-Life Care in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation. -
Rate of Rise of EBV Viral Load By Quantitative PCR after Allogeneic Transplantation Correlates with PTLD Facilitates Timely Institution of Rituximab
Muffly, L. S., Shiraz, P., Nguyen, I. T., & Brown, J. (W. M. (2016). Rate of Rise of EBV Viral Load By Quantitative PCR after Allogeneic Transplantation Correlates with PTLD Facilitates Timely Institution of Rituximab. BLOOD. AMER SOC HEMATOLOGY. -
Allogeneic Hematopoietic Cell Transplantation for Adult Acute Lymphoblastic Leukemia: Significant Increase in Survival in the Post-Targeted Immunotherapy Era
Muffly, L., Arai, S., Johnston, L., Lowsky, R., Meyer, E. H., Miklos, D. B., … Cunanan, K. (2020). Allogeneic Hematopoietic Cell Transplantation for Adult Acute Lymphoblastic Leukemia: Significant Increase in Survival in the Post-Targeted Immunotherapy Era. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 26(3), S106. -
Regulatory Type 1 T Cell Infusion in Mismatched Related or Unrelated Hematopoietic Stem Cell Transplantation (HSCT) for Hematologic Malignancies
Agarwal, R., Bacchetta, R., Bertaina, A., Chen, P., Saini, G., Shiraz, P., … Roncarolo, M. G. (2020). Regulatory Type 1 T Cell Infusion in Mismatched Related or Unrelated Hematopoietic Stem Cell Transplantation (HSCT) for Hematologic Malignancies. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. ELSEVIER SCIENCE INC. -
The Current Genomic and Molecular Landscape of Philadelphia-like Acute Lymphoblastic Leukemia.
Shiraz, P., Payne, K. J., & Muffly, L. (2020). The Current Genomic and Molecular Landscape of Philadelphia-like Acute Lymphoblastic Leukemia. International Journal of Molecular Sciences, 21(6). -
Outcomes with autologous stem cell transplant vs. non-transplant therapy in patients 70 years and older with multiple myeloma.
Lemieux, C., Muffly, L. S., Rezvani, A., Lowsky, R., Iberri, D. J., Craig, J. K., … Sidana, S. (2020). Outcomes with autologous stem cell transplant vs. non-transplant therapy in patients 70 years and older with multiple myeloma. Bone Marrow Transplantation. -
Outcomes with Autologous or Allogeneic Stem Cell Transplantation in Patients with Plasma Cell Leukemia in the Era of Novel Agents.
Lemieux, C., Johnston, L. J., Lowsky, R., Muffly, L. S., Craig, J. K., Shiraz, P., … Sidana, S. (2020). Outcomes with Autologous or Allogeneic Stem Cell Transplantation in Patients with Plasma Cell Leukemia in the Era of Novel Agents. Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation. -
CD22-Directed CAR T-Cell Therapy Induces Complete Remissions in CD19-Directed CAR-Refractory Large B-Cell Lymphoma.
Baird, J. H., Frank, M. J., Craig, J., Patel, S., Spiegel, J. Y., Sahaf, B., … Muffly, L. (2020). CD22-Directed CAR T-Cell Therapy Induces Complete Remissions in CD19-Directed CAR-Refractory Large B-Cell Lymphoma. Blood. -
Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma
Baird, J. H., Epstein, D. J., Tamaresis, J. S., Ehlinger, Z., Spiegel, J. Y., Craig, J., … Sidana, S. (2021). Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma. BLOOD ADVANCES, 5(1), 143–55. -
Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma.
Baird, J. H., Epstein, D. J., Tamaresis, J. S., Ehlinger, Z., Spiegel, J. Y., Craig, J., … Sidana, S. (2021). Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma. Blood Advances, 5(1), 143–155. -
Autologous stem cell transplantation versus no transplant in patients above 70 with multiple myeloma.
Lemieux, C., Muffly, L. S., Iberri, D. J., Rezvani, A., Lowsky, R., Frank, M. J., … Sidana, S. (2020). Autologous stem cell transplantation versus no transplant in patients above 70 with multiple myeloma. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Impact of proteasome inhibitor vs. IMiD maintenance therapy on outcomes of patients with high-risk multiple myeloma (HRMM).
Tam, E. L., Iberri, D. J., Liedtke, M., Muffly, L. S., Shiraz, P., Frank, M. J., … Sidana, S. (2020). Impact of proteasome inhibitor vs. IMiD maintenance therapy on outcomes of patients with high-risk multiple myeloma (HRMM). JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Epstein-Barr virus-positive lymphoproliferative disorder manifesting as pulmonary disease in a patient with acute myeloid leukemia: a case report.
Dutta, R., Miao, S. Y., Phan, P., Fernandez-Pol, S., Shiraz, P., Ho, D., … Zhang, T. Y. (2021). Epstein-Barr virus-positive lymphoproliferative disorder manifesting as pulmonary disease in a patient with acute myeloid leukemia: a case report. Journal of Medical Case Reports, 15(1), 170. -
Use of Backup Stem Cells for Stem Cell Boost and Second Transplant in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation.
Liang, E. C., Muffly, L. S., Shiraz, P., Shizuru, J. A., Johnston, L., Arai, S., … Sidana, S. (2021). Use of Backup Stem Cells for Stem Cell Boost and Second Transplant in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation. Transplantation and Cellular Therapy. -
Stem Cell Mobilization in Multiple Myeloma: Comparing Safety and Efficacy of Cyclophosphamide +/- Plerixafor vs. G-CSF +/- Plerixafor in the Lenalidomide Era.
Johnsrud, A., Ladha, A., Muffly, L., Shiraz, P., Goldstein, G., Osgood, V., … Sidana, S. (2021). Stem Cell Mobilization in Multiple Myeloma: Comparing Safety and Efficacy of Cyclophosphamide +/- Plerixafor vs. G-CSF +/- Plerixafor in the Lenalidomide Era. Transplantation and Cellular Therapy. -
Adoptively Transferred, In Vitro-Generated Alloantigen-Specific Type 1 Regulatory T (Tr1) Cells Persist Long-Term In Vivo
Cepika, A.-M., Chen, P. P., Agarwal, R., Saini, G., Louis, D. M., Amaya-Hernandez, L. C., … Roncarolo, M. G. (2021). Adoptively Transferred, In Vitro-Generated Alloantigen-Specific Type 1 Regulatory T (Tr1) Cells Persist Long-Term In Vivo. MOLECULAR THERAPY. CELL PRESS. -
Outcomes after delayed and second autologous stem cell transplant in patients with relapsed multiple myeloma.
Lemieux, C., Muffly, L. S., Iberri, D. J., Craig, J. K., Johnston, L. J., Lowsky, R., … Sidana, S. (2021). Outcomes after delayed and second autologous stem cell transplant in patients with relapsed multiple myeloma. Bone Marrow Transplantation. -
Inferior Clinical Outcomes in Recipients of Cryopreserved Grafts Following Reduced Intensity Allogeneic Hematopoietic Cell Transplantation: A Single Center Report
Bankova, A., Caveney, J., Ramos, T., Bogeholz, J., Heydari, K., Diaz, N., … Arai, S. (2021). Inferior Clinical Outcomes in Recipients of Cryopreserved Grafts Following Reduced Intensity Allogeneic Hematopoietic Cell Transplantation: A Single Center Report. BONE MARROW TRANSPLANTATION. SPRINGERNATURE. -
CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial.
Spiegel, J. Y., Patel, S., Muffly, L., Hossain, N. M., Oak, J., Baird, J. H., … Miklos, D. B. (2021). CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial. Nature Medicine. -
Concordance of peripheral blood and bone marrow measurable residual disease in adult acute lymphoblastic leukemia.
Muffly, L., Sundaram, V., Chen, C., Yurkiewicz, I., Kuo, E., Burnash, S., … Miklos, D. B. (2021). Concordance of peripheral blood and bone marrow measurable residual disease in adult acute lymphoblastic leukemia. Blood Advances, 5(16), 3147–3151. -
Incidence and Risk Factors Associated with Bleeding and Thrombosis Following Chimeric Antigen Receptor T Cell Therapy.
Johnsrud, A. J., Craig, J., Baird, J. H., Spiegel, J. Y., Muffly, L., Zehnder, J. L., … Sidana, S. (2021). Incidence and Risk Factors Associated with Bleeding and Thrombosis Following Chimeric Antigen Receptor T Cell Therapy. Blood Advances. -
Alloantigen-specific type 1 regulatory T cells suppress through CTLA-4 and PD-1 pathways and persist long-term in patients.
Chen, P. P., Cepika, A.-M., Agarwal-Hashmi, R., Saini, G., Uyeda, M. J., Louis, D. M., … Roncarolo, M. G. (2021). Alloantigen-specific type 1 regulatory T cells suppress through CTLA-4 and PD-1 pathways and persist long-term in patients. Science Translational Medicine, 13(617), eabf5264. -
Phase 2 study of MGTA-145+plerixafor for rapid and reliable hematopoietic stem cell (HSC) mobilization for autologous transplant in multiple myeloma.
Sidana, S., Bankova, A., Hosoya, H., Muffly, L. S., Kumar, S., Johnston, L. J., … Miklos, D. B. (2021). Phase 2 study of MGTA-145+plerixafor for rapid and reliable hematopoietic stem cell (HSC) mobilization for autologous transplant in multiple myeloma. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Incidence and risk factors associated with bleeding and thrombosis following chimeric antigen receptor T-cell therapy
Johnsrud, A., Craig, J., Baird, J., Spiegel, J., Muffly, L., Zehnder, J., … Sidana, S. (2021). Incidence and risk factors associated with bleeding and thrombosis following chimeric antigen receptor T-cell therapy. BLOOD ADVANCES, 5(21), 4465–4475. -
T-Cell Acute Lymphoblastic Leukemia-Current Concepts in Molecular Biology and Management.
Shiraz, P., Jehangir, W., & Agrawal, V. (2021). T-Cell Acute Lymphoblastic Leukemia-Current Concepts in Molecular Biology and Management. Biomedicines, 9(11). -
Real-world Experience of Cryopreserved Allogeneic Hematopoietic Grafts in the COVID-19 Pandemic: A Single Center Report.
Bankova, A. K., Caveney, J., Yao, B., Ramos, T. L., Bogeholz, J., Heydari, K., … Arai, S. (1800). Real-world Experience of Cryopreserved Allogeneic Hematopoietic Grafts in the COVID-19 Pandemic: A Single Center Report. Transplantation and Cellular Therapy. -
Allogeneic Hematopoietic Cell Transplantation for Adult Acute Lymphoblastic Leukemia in the Modern Era.
Liang, E. C., Craig, J., Torelli, S., Cunanan, K., Iglesias, M., Arai, S., … Muffly, L. (2022). Allogeneic Hematopoietic Cell Transplantation for Adult Acute Lymphoblastic Leukemia in the Modern Era. Transplantation and Cellular Therapy. -
CD22-CAR T-Cell Therapy Mediates High Durable Remission Rates in Adults with Large B-Cell Lymphoma Who Have Relapsed after CD19-CAR T-Cell Therapy
Frank, M. J., Baird, J. H., Patel, S., Craig, J., Spiegel, J. Y., Ehlinger, Z., … Muffl, L. (2021). CD22-CAR T-Cell Therapy Mediates High Durable Remission Rates in Adults with Large B-Cell Lymphoma Who Have Relapsed after CD19-CAR T-Cell Therapy. BLOOD. AMER SOC HEMATOLOGY. -
Mgta-145+Plerixafor Provides GCSFFree Rapid and Reliable Hematopoietic Stem Cell Mobilization for Autologous Stem Cell Transplant in Patients with Multiple Myeloma: A Phase 2 Study
Sidana, S., Bankova, A. K., Hosoya, H., Kumar, S., Tamaresis, J., Le, A., … Miklos, D. B. (2021). Mgta-145+Plerixafor Provides GCSFFree Rapid and Reliable Hematopoietic Stem Cell Mobilization for Autologous Stem Cell Transplant in Patients with Multiple Myeloma: A Phase 2 Study. BLOOD. AMER SOC HEMATOLOGY. -
Outcomes for Myelofibrosis Patients Following Myeloablative Allogeneic Stem Cell Transplantation Using the Orca-T Graft from HLA-Matched Related and Unrelated Donors
Arpita, G., Moroz, A., Muffly, L., Shiraz, P., Schachter, L., Fernhoff, N. B., … Meyer, E. H. (2021). Outcomes for Myelofibrosis Patients Following Myeloablative Allogeneic Stem Cell Transplantation Using the Orca-T Graft from HLA-Matched Related and Unrelated Donors. BLOOD. AMER SOC HEMATOLOGY. -
Axicabtagene ciloleucel (axi-cel) in combination with rituximab (Rtx) for the treatment (Tx) of refractory large B-cell lymphoma (R-LBCL): Outcomes of the phase 2 ZUMA-14 study.
Strati, P., Leslie, L. A., Shiraz, P., Budde, L. E., Oluwole, O. O., Ulrickson, M., … Patel, K. (2022). Axicabtagene ciloleucel (axi-cel) in combination with rituximab (Rtx) for the treatment (Tx) of refractory large B-cell lymphoma (R-LBCL): Outcomes of the phase 2 ZUMA-14 study. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Improved outcomes for relapsed/refractory Hodgkin lymphoma after autologous transplantation in the era of novel agents.
Spinner, M. A., Sica, R. A., Tamaresis, J. S., Lu, Y., Chang, C., Lowsky, R., … Arai, S. (2023). Improved outcomes for relapsed/refractory Hodgkin lymphoma after autologous transplantation in the era of novel agents. Blood. -
Outcomes for Acute Myeloid Leukemia Relapse after Allogeneic Hematopoietic Cell Transplantation Remain Poor in the Modern Era
Philip, S., Lowsky, R., Johnston, L. J., Arai, S., Meyer, E. H., Negrin, R. S., … Agrawal, V. (2022). Outcomes for Acute Myeloid Leukemia Relapse after Allogeneic Hematopoietic Cell Transplantation Remain Poor in the Modern Era. BLOOD. AMER SOC HEMATOLOGY. -
Belumosudil Combination Therapy in Refractory Chronic Graft-Versus-Host Disease
Chin, M., Shizuru, J. A., Muffly, L., Shiraz, P., Johnston, L. J., Lowsky, R., … Arai, S. (2022). Belumosudil Combination Therapy in Refractory Chronic Graft-Versus-Host Disease. BLOOD. AMER SOC HEMATOLOGY. -
Ultra-Sensitive Next-Generation Sequencing Establishes the Prognostic Value of Very Low MRD in Adults with Acute Lymphoblastic Leukemia Undergoing Hematopoietic Cell Transplantation
Liang, E. C., Dekker, S. E., Sabile, J. M. G., Torelli, S., Zhang, A., Miller, K., … Muffly, L. (2022). Ultra-Sensitive Next-Generation Sequencing Establishes the Prognostic Value of Very Low MRD in Adults with Acute Lymphoblastic Leukemia Undergoing Hematopoietic Cell Transplantation. BLOOD. AMER SOC HEMATOLOGY. -
Analysis of Bendamustine Lymphodepletion, CD19 CART Expansion, Safety and Efficacy in Patients with Rel/Ref NonHodgkin Lymphoma
Bharadwaj, S., Hamilton, M. P., Sahaf, B., Tamaresis, J., Patil, S., Hanson, P. J., … Dahiya, S. (2022). Analysis of Bendamustine Lymphodepletion, CD19 CART Expansion, Safety and Efficacy in Patients with Rel/Ref NonHodgkin Lymphoma. BLOOD. AMER SOC HEMATOLOGY. -
The Development of Carhlh after Axicabtagene Ciloleucel Is Associated with Poor Outcomes
Philip, S., Srinagesh, H. K., Hamilton, M. P., Gentille, C., Mina, A., Arai, S., … Frank, M. J. (2022). The Development of Carhlh after Axicabtagene Ciloleucel Is Associated with Poor Outcomes. BLOOD. AMER SOC HEMATOLOGY. -
Higher Rates of Severe Infection and Persistent Cytopenias in Long-Term CAR19 Responders Than after Autologous HCT: A Single Institution Study of 139 Subjects
Hamilton, M. P., Liu-Fei, F. C., Alig, S. K., Tamaresis, J., Esfahani, M. S., Good, Z., … Alizadeh, A. A. (2022). Higher Rates of Severe Infection and Persistent Cytopenias in Long-Term CAR19 Responders Than after Autologous HCT: A Single Institution Study of 139 Subjects. BLOOD. AMER SOC HEMATOLOGY. -
ZUMA-19: A Phase 1/2 Study of Axicabtagene Ciloleucel Plus Lenzilumab in Patients With Relapsed or Refractory Large B-Cell Lymphoma
Oluwole, O. O., Kenderian, S. S., Shiraz, P., Karmali, R., Reshef, R., McCarthy, P. L., … Neelapu, S. S. (2022). ZUMA-19: A Phase 1/2 Study of Axicabtagene Ciloleucel Plus Lenzilumab in Patients With Relapsed or Refractory Large B-Cell Lymphoma. BLOOD. AMER SOC HEMATOLOGY. -
Next-Generation Sequencing-Based MRD in Adults with ALL Undergoing Hematopoietic Cell Transplantation.
Liang, E. C., Dekker, S. E., Sabile, J. M., Torelli, S., Zhang, A., Miller, K., … Muffly, L. (2023). Next-Generation Sequencing-Based MRD in Adults with ALL Undergoing Hematopoietic Cell Transplantation. Blood Advances. -
Single Center Randomized Trial of T-reg graft alone versus T-reg graft Plus Tacrolimus for the Prevention of Acute GVHD.
Bader, C. S., Pavlova, A., Lowsky, R., Muffly, L., Shiraz, P., Arai, S., … Meyer, E. (2023). Single Center Randomized Trial of T-reg graft alone versus T-reg graft Plus Tacrolimus for the Prevention of Acute GVHD. Blood Advances. -
CAR19 Therapy Drives Expansion of Clonal Hematopoiesis and Associated Cytopenias
Hamilton, M. P., Sworder, B. J., Alig, S. K., Good, Z., Boegeholz, J., Schroers-Martin, J., … Alizadeh, A. A. (2023). CAR19 Therapy Drives Expansion of Clonal Hematopoiesis and Associated Cytopenias. BLOOD. AMER SOC HEMATOLOGY.
Clinical Trials
Clinical trials are research studies that evaluate a new medical approach, device, drug, or other treatment. As a Stanford Health Care patient, you may have access to the latest, advanced clinical trials.
Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.
- A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies »
- Safety of Myeloablative Conditioning, Orca-T, and Allogeneic, Donor-Derived CD19/CD22-CAR (Chimeric Antigen Receptor) T Cells in Adults With B-cell Acute Lymphoblastic Leukemia (ALL) »
- Evaluate Safety of Axicabtagene Ciloleucel Reinfusion (Axi-Cel-2) in Patients With Relapsed and/or Refractory Second Line High-Risk Non-Hodgkin Lymphoma After Standard of Care Axi-Cel »
- Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Rituximab in Participants With Refractory Large B-Cell Lymphoma »
- Study of Lenzilumab and Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma »
- Treatment of GVHD in Hematopoietic Stem Cell Transplant (HSCT) Recipients Using AAT Plus Corticosteroids (CS) Compared With Corticosteroids Alone (BMT CTN 1705) »
- CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refractory B Cell Malignancies »
- Autologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies »
- Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC) »
Practice Locations
Blood and Marrow Transplant Program (BMT) - 875 Blake Wilbur Drive Palo Alto, CA
Palo Alto, CA
Blood and Marrow Transplant Program (BMT) - 875 Blake Wilbur Drive
875 Blake Wilbur Drive, Clinic E, 1st Floor
Palo Alto , CA 94304
Make An Appointment More Clinic Information » Getting Here »Important Information about Our Organizations and Physician Affiliation
Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners are each independent nonprofit organizations that are affiliated with but separate from each other and from Stanford University. The physicians who provide care at facilities operated by Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners are faculty, foundation, or community physicians who are not employees, representatives, or agents of Stanford Health Care, Stanford Health Care Tri- Valley, or Stanford Medicine Partners. Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners do not exercise control over the care provided by such faculty, foundation, and community physicians and are not responsible for their actions.
Patient Reviews
(37 reviews)
Dr Shiraz is an excellent doctor
Dr Shiraz is a very caring person.
Excellent care team, Dr. Shiraz, Maqui N, and the scribe!
Thank you for listening my problems, and provide solutions for me! I feel being supported!
Near end of time for chat with Dr. Shiraz, it appeared she was reading from a script
I like talking to her and I feel much better then when I talk to Kaiser
She’s great. Gives me a great sense of security.
And her team, is equally as good. I’m so grateful for Stanford, Dr Shiraz, and my entire treatment team at that facility.
My visit was very beneficial. I got the information and details of what the BMT procedure would entail and what is required of me as a patient. It was a great experience visiting your site.
Dr. Shiraz was very patient, answering all my question, assured me for my concerns. I appreciated very much!
Dr. Shiraz is a very caring physician. She was patient to my questions, answered them all. And she emphasized the important things for me to remember. I am very fortunate to Dr. Shiraz as my BMT doctor, and very thankful to Stanford BMT team!
I give Dr. Shiraz and her team the credit for saving my life after having and
being treated for acute myeloid leukemia. She is the best.
accommodating with my special needs, patient with my questions, caring, supporting in dealing with my illness
Very knowledgeable friendly Doctor. Put me at ease
Everyone we met with was very informative and helpful and answered all of our questions.
GreT physician. Really care about me the patient. Make me feel like I am only one in room. She is not distracted to other patients or hospital staff when we are talking
She’s very professional caring and understanding we just love her
Excellent Dr.
I admire her. She was for a time my doctor at Kaiser. I liked her then, I like her now. She is personable, articulate, very competent, willing to listen, and has concern for her patients and the outcomes of the procedures they are about to undertake. She's a damm good doctor.
Very informative, caring, and reassuring staff.
Good people Good information efficient
Very pleased to meet with Dr. Shiraz. I felt very comfortable asking questions and understood all answers. Extremely happy I didn't have to drive down to Medical Center and could meet through video.
She was concise and explained everything so I could understand it all and seemed really caring about me and my situation. Thank you to both her and her assistant Felipe.
Skilled and attentive to us and details of treatment
We appreciate greatly Dr Shiraz's detailed care and concern. She communicates clearly and expresses genuine interest in her patients. We are most pleased that she is our oncologist at Stanford. We know we are in good hands!
She is a very compassionate doctor
Dr. Shiraz was very thorough and I am very pleased with the care and attention she has given to my medical needs.
Excellent care and very professional.
Dr . shiraz always ask the questions that we need to answer in order to improve patients health , and patients can make the necessary questions regarding health problems .
Dr. Shiraz is an outstanding medical provider. She makes medical statements that the non medical patient can understand.
She make you feel comfortable in your conversation, she is concerned about your welfare as a human and seems genuinely concerned about you
Very understanding and caring.
She and her Nurse coordinator Marqui was also very professional and friendly.
She is very knowledgeable and she gave me clear and concise information about my condition.
Very thorough and helpful. Provided information helpful to me and my recovery.
Dr Shiraz has all the answers to my questions
Excellent
Very pleased with Dr. Shiraz & her entire staff. Very professional and informative about my care/questions/concerns.
Dr. Shiraz is very knowledgeable. She gives clear and concise information about my condition, medications, and prognosis. She is a good listener, caring, and empathetic. Dr. Shiraz is an excellent doctor.
Dr. Shiraz is knowledgeable, kind, and caring I am glad she is my Doctor.
View More »
Referring Physicians
PHYSICIAN HELPLINE
Phone: 1-866-742-4811
Fax: 650-320-9443
Monday–Friday, 8 a.m.–5 p.m.
Fax: 650-320-9443
Monday–Friday, 8 a.m.–5 p.m.
Stanford Health Care provides comprehensive services to refer and track patients, as well as the latest information and news for physicians and office staff. For help with all referral needs and questions, visit Referral Information.
You may also submit a web referral or complete a referral form and fax it to 650-320-9443 or email the Referral Center at ReferralCenter@stanfordhealthcare.org.
- Send referrals online
- Place radiology and lab orders
- View referral status
- Access medical records